Biobanking of patient and patient-derived xenograft ovarian tumour tissue: Efficient preservation with low and high fetal calf serum based methods

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Alkema, Nicolette G ^a   Tomar, Tushar ^a   Duiker, Evelien W ^a   Jan Meersma, Gert ^a   Klip, Harry ^a   Van Der Zee, Ate G J ^a   Wisman, G Bea A ^a   De Jong, Steven ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CRYOPROTECTIVE AGENT;

ANIMAL; BIOBANK; BOVINE; CANCER TRANSPLANTATION; CELL CULTURE TECHNIQUE; CRYOPRESERVATION; FEMALE; FETUS BLOOD; HUMAN; MOUSE; NONOBESE DIABETIC MOUSE; OVARIAN NEOPLASMS; PATHOLOGY; PROCEDURES; SCID MOUSE; TISSUE SURVIVAL; VITRIFICATION; XENOGRAFT;

ANIMALS; BIOLOGICAL SPECIMEN BANKS; CATTLE; CELL CULTURE TECHNIQUES; CRYOPRESERVATION; CRYOPROTECTIVE AGENTS; FEMALE; FETAL BLOOD; HUMANS; MICE; MICE, INBRED NOD; MICE, SCID; NEOPLASM TRANSPLANTATION; OVARIAN NEOPLASMS; TISSUE SURVIVAL; TRANSPLANTATION, HETEROLOGOUS; VITRIFICATION;

EID: 84943311487     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep14495     Document Type: Article

References (44)

1. Vaughan, S. et al. Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer 11, 719-725, doi: 10.1038/nrc3144 (2011).
2. Elkas, J. C. et al. A human ovarian carcinoma murine xenograft model useful for preclinical trials. Gynecol Oncol 87, 200-206 (2002).
3. Kleine, W. Prognostic significance of growth characteristics of xenotransplanted ovarian carcinomas into nude mice. Gynecol Oncol 25, 65-72 (1986).
4. Lee, C. H. et al. Establishment of subrenal capsule xenografts of primary human ovarian tumors in SCID mice: potential models. Gynecol Oncol 96, 48-55, doi: 10.1016/j.ygyno.2004.09.025 (2005).
5. Xu, Y. et al. Characterization of human ovarian carcinomas in a SCID mouse model. Gynecol Oncol 72, 161-170, doi: 10.1006/gyno.1998.5238 (1999).
6. Siolas, D., Hannon, G. J. Patient-derived tumor xenografts: transforming clinical samples into mouse models. Cancer research 73, 5315-5319, doi: 10.1158/0008-5472.CAN-13-1069 (2013).
7. DeRose, Y. S. et al. Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nat Med 17, 1514-1520, doi: 10.1038/nm.2454 (2011).
8. Fichtner, I. et al. Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers. Clin Cancer Res 14, 6456-6468, doi: 10.1158/1078-0432.CCR-08-0138 (2008).
9. Zhao, X. et al. Global gene expression profiling confirms the molecular fidelity of primary tumor-based orthotopic xenograft mouse models of medulloblastoma. Neuro Oncol 14, 574-583, doi: 10.1093/neuonc/nos061 (2012).
10. Ricci, F. et al. Patient-derived ovarian tumor xenografts recapitulate human clinicopathology and genetic alterations. Cancer Res, doi: 0008-5472.CAN-14-0274 [pii] 10.1158/0008-5472.CAN-14-0274 (2014).
11. Rubio-Viqueira, B. et al. An in vivo platform for translational drug development in pancreatic cancer. Clin Cancer Res 12, 4652-4661, doi: 10.1158/1078-0432.CCR-06-0113 (2006).
12. Morton, C. L., Houghton, P. J. Establishment of human tumor xenografts in immunodeficient mice. Nat Protoc 2, 247-250, doi: 10.1038/nprot.2007.25 (2007).
13. Reyal, F. et al. Molecular profiling of patient-derived breast cancer xenografts. Breast Cancer Res 14, R11, doi: 10.1186/bcr3095 (2012).
14. Garrido-Laguna, I. et al. Tumor engraftment in nude mice and enrichment in stroma-related gene pathways predict poor survival and resistance to gemcitabine in patients with pancreatic cancer. Clin Cancer Res 17, 5793-5800, doi: 10.1158/1078-0432. CCR-11-0341 (2011).
15. Fiebig, H. H., Maier, A., Burger, A. M. Clonogenic assay with established human tumour xenografts: correlation of in vitro to in vivo activity as a basis for anticancer drug discovery. Eur J Cancer 40, 802-820, doi: 10.1016/j.ejca.2004.01.009 (2004).
16. Johnson, J. I. et al. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br J Cancer 84, 1424-1431, doi: 10.1054/bjoc.2001.1796 (2001).
17. Tentler, J. J. et al. Patient-derived tumour xenografts as models for oncology drug development. Nat Rev Clin Oncol 9, 338-350, doi: 10.1038/nrclinonc.2012.61 (2012).
18. Voskoglou-Nomikos, T., Pater, J. L., Seymour, L. Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. Clin Cancer Res 9, 4227-4239 (2003).
19. Dangles-Marie, V. et al. Establishment of human colon cancer cell lines from fresh tumors versus xenografts: comparison of success rate and cell line features. Cancer research 67, 398-407, doi: 10.1158/0008-5472.CAN-06-0594 (2007).
20. Sheikhi, M., Hultenby, K., Niklasson, B., Lundqvist, M., Hovatta, O. Clinical grade vitrification of human ovarian tissue: an ultrastructural analysis of follicles and stroma in vitrified tissue. Hum Reprod 26, 594-603, doi: 10.1093/humrep/deq357 (2011).
21. Sieh, W. et al. Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. The Lancet. Oncology 14, 853-862, doi: 10.1016/S1470-2045(13)70253-5 (2013).
22. Bankert, R. B. et al. Humanized mouse model of ovarian cancer recapitulates patient solid tumor progression, ascites formation, and metastasis. PLoS One 6, e24420, doi: 10.1371/journal.pone.0024420 (2011).
23. Kolfschoten, G. M. et al. Development of a panel of 15 human ovarian cancer xenografts for drug screening and determination of the role of the glutathione detoxification system. Gynecol Oncol 76, 362-368, doi: 10.1006/gyno.1999.5689 (2000).
24. Marangoni, E. et al. A new model of patient tumor-derived breast cancer xenografts for preclinical assays. Clin Cancer Res 13, 3989-3998, doi: 10.1158/1078-0432.CCR-07-0078 (2007).
25. Vidal, A. et al. Lurbinectedin (PM01183), a new DNA minor groove binder, inhibits growth of orthotopic primary graft of cisplatin-resistant epithelial ovarian cancer. Clin Cancer Res 18, 5399-5411, doi: 10.1158/1078-0432.CCR-12-1513 (2012).
26. Cui, J. H. et al. Intact tissue of gastrointestinal cancer specimen orthotopically transplanted into nude mice. Hepatogastroenterology 45, 2087-2096 (1998).
27. Cui, J. H., Krueger, U., Henne-Bruns, D., Kremer, B., Kalthoff, H. Orthotopic transplantation model of human gastrointestinal cancer and detection of micrometastases. World J Gastroenterol 7, 381-386 (2001).
28. Sorio, C. et al. Successful xenografting of cryopreserved primary pancreatic cancers. Virchows Arch 438, 154-158 (2001).
29. Linnebacher, M. et al. Cryopreservation of human colorectal carcinomas prior to xenografting. BMC Cancer 10, 362, doi: 10.1186/1471-2407-10-362 (2010).
30. Amorim, C. A., Curaba, M., Van Langendonckt, A., Dolmans, M. M., Donnez, J. Vitrification as an alternative means of cryopreserving ovarian tissue. Reprod Biomed Online 23, 160-186, doi: 10.1016/j.rbmo.2011.04.005 (2011).
31. Hovatta, O. Methods for cryopreservation of human ovarian tissue. Reprod Biomed Online 10, 729-734 (2005).
32. Kuleshova, L. L., Lopata, A. Vitrification can be more favorable than slow cooling. Fertil Steril 78, 449-454 (2002).
33. Mukaida, T., Oka, C. Vitrification of oocytes, embryos and blastocysts. Best Pract Res Clin Obstet Gynaecol 26, 789-803, doi: 10.1016/j.bpobgyn.2012.07.001 (2012).
34. Hylander, B. L. et al. Origin of the vasculature supporting growth of primary patient tumor xenografts. J Transl Med 11, 110, doi: 10.1186/1479-5876-11-110 (2013).
35. Cunat, S., Hoffmann, P., Pujol, P. Estrogens and epithelial ovarian cancer. Gynecol Oncol 94, 25-32, doi: 10.1016/j. ygyno.2004.03.026 (2004).
36. Hidalgo, M. et al. Patient-derived xenograft models: an emerging platform for translational cancer research. Cancer Discov 4, 998-1013, doi: 10.1158/2159-8290.CD-14-0001 (2014).
37. Scott, C. L., Becker, M. A., Haluska, P., Samimi, G. Patient-derived xenograft models to improve targeted therapy in epithelial ovarian cancer treatment. Front Oncol 3, 295, doi: 10.3389/fonc.2013.00295 (2013).
38. Press, J. Z. et al. Xenografts of primary human gynecological tumors grown under the renal capsule of NOD/SCID mice show genetic stability during serial transplantation and respond to cytotoxic chemotherapy. Gynecol Oncol 110, 256-264, doi: 10.1016/j. ygyno.2008.03.011 (2008).
39. Li, S. et al. Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. Cell Rep 4, 1116-1130, doi: S2211-1247(13)00463-4 [pii] 10.1016/j.celrep.2013.08.022 (2013).
40. Topp, M. D. et al. Molecular correlates of platinum response in human high-grade serous ovarian cancer patient-derived xenografts. Mol Oncol 8, 656-668, doi: 10.1016/j.molonc.2014.01.008 (2014).
41. Weroha, S. J. et al. Tumorgrafts as in vivo surrogates for women with ovarian cancer. Clin Cancer Res 20, 1288-1297, doi: 10.1158/1078-0432.CCR-13-2611 (2014).
42. Hammond, M. E. et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28, 2784-2795, doi: 10.1200/JCO.2009.25.6529 (2010).
43. van Dongen, J. J. et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 17, 2257-2317, doi: 10.1038/sj.leu.2403202 (2003).
44. Bertotti, A. et al. A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov 1, 508-523, doi: 2159-8290.CD-11-0109 [pii] 10.1158/2159-8290.CD-11-0109 (2011).